These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35940587)

  • 21. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
    Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
    Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
    Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study.
    Zdovc J; Petre M; Pišlar M; Repnik K; Mrhar A; Vogrin M; Potočnik U; Grabnar I
    Eur J Clin Pharmacol; 2019 Jun; 75(6):817-824. PubMed ID: 30725221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.
    Roşian AN; Roşian ŞH; Kiss B; Ştefan MG; Trifa AP; Ober CD; Anchidin O; Buzoianu AD
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32316515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China.
    Liu L; Hong D; Ma K; Lu X
    J Clin Pharm Ther; 2021 Jun; 46(3):658-668. PubMed ID: 33226144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience.
    Akhtar T; Fratti JDC; Mattumpuram J; Fugar S; Uprety A; Nwaichi C; Torres A; Mann H; Golzar Y
    Int J Cardiol; 2020 Dec; 320():78-82. PubMed ID: 32598991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
    Norby FL; Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Chamberlain AM; Rapson I; Alonso A
    BMC Cardiovasc Disord; 2017 Sep; 17(1):238. PubMed ID: 28874129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study.
    Evans A; Davies M; Osborne V; Roy D; Shakir S
    PLoS One; 2020; 15(10):e0240489. PubMed ID: 33035259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
    Ji Q; Zhang C; Xu Q; Wang Z; Li X; Lv Q
    Br J Clin Pharmacol; 2021 May; 87(5):2247-2255. PubMed ID: 33179295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ABCB1 Genotypes on the Pharmacokinetics and Clinical Outcomes of New Oral Anticoagulants: A Systematic Review and Meta-analysis.
    Xie Q; Xiang Q; Mu G; Ma L; Chen S; Zhou S; Hu K; Zhang Z; Cui Y; Jiang J
    Curr Pharm Des; 2018; 24(30):3558-3565. PubMed ID: 30338730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
    Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia.
    Liu PY; Choi EK; Kim TS; Kuo JY; Lee JM; On YK; Park SW; Park HW; Shin DG; Wang L; Yen HW; Lee MH;
    Adv Ther; 2022 Jul; 39(7):3316-3333. PubMed ID: 35616848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
    Sychev D; Skripka A; Ryzhikova K; Bochkov P; Shevchenko R; Krupenin P; Ivashchenko D; Kogay V; Listratov A; Krainyaya A; Gurinovich O; Sokolova A; Napalkov D; Fomin V
    Drug Metab Pers Ther; 2020 Mar; 35(1):. PubMed ID: 32134727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation.
    Yanagisawa D; Abe K; Amano H; Komatsuda S; Honda T; Manabe D; Yamamoto H; Kozuma K; Kodashima S; Asaoka Y; Yamamoto T; Tanaka A
    PLoS One; 2021; 16(11):e0260585. PubMed ID: 34843582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.
    Lamberts M; Staerk L; Olesen JB; Fosbøl EL; Hansen ML; Harboe L; Lefevre C; Evans D; Gislason GH
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28196815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Efficacy and Safety of Oral Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation Scheduled for Electrical Cardioversion.
    Enomoto Y; Ito N; Fujino T; Noro M; Ikeda T; Sugi K
    Intern Med; 2016; 55(15):1953-8. PubMed ID: 27477399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF.
    Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR; Melloni C
    Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):145-152. PubMed ID: 30219887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.